Document is current
Any future updates will be listed below
-
Authors
Borriello, Lucia
Coste, Anouchka
Traub, Brian
Sharma, Ved P.
Karagiannis, George S.
Lin, Yu
Wang, Yarong
Ye, Xianjun https://orcid.org/0000-0002-1136-4040
Duran, Camille L. https://orcid.org/0000-0002-7614-3265
Chen, Xiaoming
Friedman, Madeline
Sosa, Maria Soledad
Sun, Dan
Dalla, Erica
Singh, Deepak K.
Oktay, Maja H.
Aguirre-Ghiso, Julio A.
Condeelis, John S. https://orcid.org/0000-0001-8826-2336
Entenberg, David https://orcid.org/0000-0003-0422-7264
-
Funding
Funding for this research was provided by:
NCI grant
- License Information
-
More Information
Article History
Received: 12 March 2021
Accepted: 7 January 2022
First Online: 2 February 2022
Competing interests
: Dr. Julio Aguirre-Ghiso is a scientific Co-Founder of, Scientific Advisory Board Member, and equity owner in the private company, HiberCell, LLC. In addition, Dr. Aguirre-Ghiso receives financial compensation as a consultant for HiberCell, LLC. HiberCell, LLC. is a Mount Sinai spin-out company focused on the research and development of therapeutics that prevent or delay the recurrence of cancer. The remaining authors declare no competing interests.
